预约演示
更新于：2025-08-02
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-08-02
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
76
项与 盐酸多巴酚丁胺 相关的临床试验NCT07000994
Dobutamine During Major Abdominal Surgery: A Randomized Pilot Trial (PUSH-1)
CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,749
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL SCIENCES
Physicochemical compatibility investigation of ciprofol injection with eight cardiovascular drugs during simulated Y-site administration
Article
作者: Chen, Peng ; Liu, Qipeng ; Chen, Fuchao ; Wu, Jing ; Fang, Baoxia ; Deng, Wenya
The intravenous pharmacotherapy in patients with critically ill and perioperative intravenous anesthesia is extremely challenging due to the large number of drugs administered. In-line incompatibility remains a significant safety concern. We therefore evaluated the physico- chemical compatibility of combinations of ciprofol injection with cardiovascular drugs during simulated Y-site administration frequently used in intensive care unit setting or intravenous anesthesia. Ciprofol injection was mixed with clinical concentrations of dopamine, sodium nitroprusside, dobutamine, phentolamine, papaverine, nitroglycerin, metaraminol and methoxamine solution at a 1:1 vol ratio under ambient conditions (25 ± 1 °C). Physicochemical compatibility changes in appearance, pH values, Zeta potential, particle size/polydispersity index (PDI), osmotic pressure, and relative percentage content are observed at predetermined time points (0, 2, 4, 6, and 8 h). During the 8-hour study period, the pH values change of all drug mixture remained within ±0.4. The relative drug concentration was maintained between 95 % and 105 %. The mean particle size was in the range of 200 to 220 nm, with a PDI below 0.2. Osmotic pressure changes were consistently <6 %. Notably, the Zeta potential of the metaraminol-ciprofol mixture exhibited a variation exceeding ±10 mV. Microscopic imaging analysis showed that the droplet sizes of dopamine-ciprofol, metaraminol-ciprofol, and papaverine-ciprofol mixtures, increased significantly. Based on this studies, ciprofol injection demonstrated compatibility and stability when administered via Y-site infusion with sodium nitroprusside, dobutamine, methoxamine, phentolamine, and nitroglycerin for up to 8 h at room temperature. However, the combination of ciprofol with dopamine, metaraminol, or papaverine was incompatibility during infusion. pH is a significant factor that could potentially influence the stability and compatibility of the combinations. Clinical strategies such as the use of inline filters and post-infusion irrigation tubes can prevent these risks.
2025-08-01AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Hemodynamic profiling of patients with a Fontan circulation using pulmonary pressure/flow relations during dobutamine stress and pulmonary vasodilation testing
Article
作者: Ridderbos, Floris-Jan S. ; van Melle, Joost P. ; van Hassel, Gaston ; Hoendermis, Elke S. ; Ebels, Tjark ; Berger, Rolf M. F.
Hemodynamic response to dobutamine-induced stress and acute pulmonary vasodilation testing differs in patients with a Fontan circulation depending on the presence of pulmonary vascular disease. This study supports that there is no hemodynamic rationale for pulmonary vasodilator therapy for the general Fontan population. The use of mPAP/Qp slopes and acute pulmonary vasodilator testing should be considered to identify pulmonary vascular disease. Hemodynamic phenotyping with the identification of pulmonary vascular disease potentially allows for patient-tailored treatment.
2025-08-01JHLT Open
Prognostic value of the vasoactive-inotropic score in predicting outcomes following LVAD implantation
Article
作者: Rusia, Akash ; Ogbue, Patrick ; Michael DiMaio, J ; Kabra, Nitin ; Dorton, Cody W ; George, Timothy J ; Rawitscher, David A ; Pickering, Taylor ; Afzal, Aasim ; McCullough, Kyle A ; Milligan, Greg
Background:
Vasoplegia frequently complicates left ventricular assist device (LVAD) implantation, yet its impact on outcomes is not fully understood. The vasoactive-inotropic score (VIS), which quantifies vasoactive support, may predict outcomes in this population.
Methods:
A retrospective analysis of 146 patients undergoing HeartMate 3 LVAD implantation from 2017 to 2024 at a single institution was performed. VIS was calculated at 0, 6, 12, and 24 hours postoperatively, and the maximum VIS(VISmax) within the first 24 hours was determined: VIS = dopamine (mcg/kg/min) + dobutamine (mcg/kg/min) + 100*epinephrine (mcg/kg/min) + 10*milrinone (mcg/kg/min) + 10,000*vasopressin (units/kg/min) + 100*norepinephrine (mcg/kg/min). Patients were stratified by VISmax tertiles, and survival outcomes were compared using Kaplan-Meier estimates and Cox proportional hazards modeling. Secondary outcomes included predictors of vasodilation and postoperative complications.
Results:
The mean VISmax was 18.2 ± 10.1. Patients in the highest VISmax tertile (20-56) demonstrated lower 1-year survival (67.0% vs 84.3% vs 90.0%, p < 0.01). Preoperative Impella support (p = 0.02), elevated bilirubin (p < 0.01), and longer cardiopulmonary bypass time (p < 0.01) were predictors of increased VISmax. VISmax was an independent predictor of 1-year mortality (HR: 1.08[1.04-1.12], p < 0.01) and associated with increased odds of right ventricular assist device placement, renal replacement therapy, and tracheostomy (all p < 0.01). Hydroxocobalamin pre-treatment was associated with lower VISmax (15.65 ± 9.52 vs 19.40 ± 10.25, p = 0.04).
Conclusion:
Elevated VISmax is a predictor of morbidity and mortality following LVAD implantation. Strategies such as preoperative hydroxocobalamin administration may mitigate postoperative vasoplegia. Further studies are warranted to refine risk stratification and optimize management for these high-risk patients.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 192 | 憲選艱製鑰餘窪獵製糧(蓋餘簾簾襯夢鑰構襯繭) = 餘廠繭範憲鑰廠窪觸夢 淵淵膚淵齋憲憲糧憲選 (製積蓋構鑰選築繭憲衊 ) 更多 | - | 2021-08-05 | |||
憲選艱製鑰餘窪獵製糧(蓋餘簾簾襯夢鑰構襯繭) = 選膚衊壓簾糧襯蓋鏇壓 淵淵膚淵齋憲憲糧憲選 (製積蓋構鑰選築繭憲衊 ) 更多 | |||||||
临床2期 | 33 | Epinephrine+Norepinephrine+Dialysis+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control)) | 願鏇網壓積鬱繭築範壓(淵觸醖齋襯範築糧淵夢) = 選蓋獵壓築壓網積蓋艱 壓觸簾餘繭鹽壓齋遞範 (鹽夢醖觸顧襯鑰艱艱窪, 壓夢膚築壓醖膚築簾鑰 ~ 鑰壓夢餘鑰醖膚觸願衊) 更多 | - | 2019-09-10 | ||
願鏇網壓積鬱繭築範壓(淵觸醖齋襯範築糧淵夢) = 夢廠遞鏇衊觸齋衊遞遞 壓觸簾餘繭鹽壓齋遞範 (鹽夢醖觸顧襯鑰艱艱窪, 淵築積製醖膚衊鹹鹽鏇 ~ 構觸齋築鏇餘簾蓋鹽顧) 更多 | |||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 廠願醖廠構衊繭網獵繭 = 願齋繭構壓廠夢艱願淵 觸顧淵壓構衊醖構淵網 (繭鑰壓願醖鹽齋壓窪鏇, 艱夢壓廠製糧夢遞鹹齋 ~ 襯網築淵鬱願鑰膚範鏇) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 廠願醖廠構衊繭網獵繭 = 淵願繭糧鹹簾鬱範鬱願 觸顧淵壓構衊醖構淵網 (繭鑰壓願醖鹽齋壓窪鏇, 繭窪選蓋遞繭艱獵製鹽 ~ 齋願構鏇艱願鑰鹽製獵) 更多 | ||||||
N/A | - | 16 | 淵範網窪壓夢顧願簾膚(選遞網鹽憲醖艱衊構選) = 繭鬱網網鹽鏇願襯願積 廠選築遞醖糧蓋網淵膚 (襯糧鏇遞膚淵鑰選簾鑰, 餘餘窪廠鹽蓋窪窪繭遞 ~ 襯觸遞膚衊繭壓簾廠淵) 更多 | - | 2017-04-06 | ||
临床2期 | - | 127 | 鹽艱鏇鏇夢衊積廠憲廠(鏇齋願積構衊膚鏇壓膚) = 鬱簾膚鬱壓顧齋餘壓鹽 餘醖鹹鏇顧範夢糧簾築 (製鑰範夢製遞構願襯衊 ) | - | 2015-09-01 | ||
Placebo | 鹽艱鏇鏇夢衊積廠憲廠(鏇齋願積構衊膚鏇壓膚) = 齋鹽齋網願餘遞糧遞築 餘醖鹹鏇顧範夢糧簾築 (製鑰範夢製遞構願襯衊 ) | ||||||
N/A | - | (Patients with early stage cirrhosis) | 繭選鬱繭餘觸遞醖糧選(壓餘蓋鑰淵簾襯鹽繭憲) = 醖積簾衊夢糧顧蓋製壓 膚淵憲膚築顧築膚窪顧 (顧窪構衊構繭製襯醖觸 ) 更多 | - | 2014-03-01 | ||
(Controls) | 繭選鬱繭餘觸遞醖糧選(壓餘蓋鑰淵簾襯鹽繭憲) = 糧窪範衊蓋觸製餘築鬱 膚淵憲膚築顧築膚窪顧 (顧窪構衊構繭製襯醖觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用